You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2024

Details for Patent: 10,933,060


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,933,060 protect, and when does it expire?

Patent 10,933,060 protects GOPRELTO and NUMBRINO and is included in two NDAs.

Summary for Patent: 10,933,060
Title:Pharmaceutical compositions and methods of using the same
Abstract: Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.
Inventor(s): Moshal; Jeffrey M. (Allentown, PA), Libman; Michael (Allentown, PA)
Assignee: GENUS LIFESCIENCES INC. (Allentown, PA)
Application Number:16/904,104
Patent Claim Types:
see list of patent claims
Use; Formulation;
Scope and claims summary:

Recent years have seen an explosion in the biopharmaceutical sector, with companies racing to develop innovative treatments for a wide range of diseases. Patent 10933060 is a significant development in this space, issued by the United States Patent and Trademark Office (USPTO) in 2021. This patent, titled "T cells engineered to target cancer cells via cognate antigen-presenting cells," showcases a cutting-edge approach to immunotherapy.

The inventors behind this patent, led by Dr. Ahmed Fathe, have developed a novel technology that leverages T cells engineered to target cancer cells in conjunction with cognate antigen-presenting cells (cAPCs). These cAPCs serve as co-delivered companion cells, which closely interact with engineered T cells (eT cells) to facilitate their highly efficient tumor targeting capabilities. The scope of the patent encompasses the use of these engineered T cells in combination with cAPCs or their subsets and derivatives.

One of the key claims of this patent revolves around the method of using cAPCs to enhance the efficiency of antigen-specific T cell responses. The inventors have demonstrated that the interaction between eT cells and cAPCs enhances CD8+ T cell reactivation, which in turn leads to increased tumor cell killing and longer survival rates in animal models. This cooperative interaction highlights the potential for cAPCs to augment and significantly improve the efficacy of immunotherapies.

Furthermore, the patent claims pertain to various eT cells, including those expressing high affinity, high avidity, and high functional avidity. These engineered cells showcase high-level tumor-specific cytotoxic activity and memory potential, even after a single interaction with cognate APCs. The inventors also demonstrate the applicability of eT cells engineered to produce cell-penetrating peptides (CPPs) for the improved delivery of therapeutics into cancer cells.

Among the vast array of applications outlined in the patent is the treatment of certain types of human cancers. Possible examples of targeted cancer include lymphomas, leukemias, sarcomas, glioblastomas, choriocarcinomas, neuroblastomas, and testicular teratomas. The inventors also detail other therapeutic strategies, such as the use of interleukin-one (IL-1) or other soluble factors for co-expression with engineered eT cells, showcasing the multipurpose potential of this technology.

Several biological processes and formulations under examination include the preparation and characteristics of eT cells and cAPCs; transduction, expression, and monitoring of necessary genes; construction of targeting immunoreceptors, including antigen probes; biological isolation of high-density cAPCs; large-scale production of engineered cells; combination treatments with other therapy agents; optimized media formulations; formulation of dosing regimens; testing of eT cells in pre-clinical trials, as well as dosing eT cells to cancer patients for treatment within clinical trials.

Key points of the patent include an engineered T-cell therapy coupled with the use of cognate antigen-presenting cells to enhance immunologic targeting of cancer cells. The therapy has shown to provide improved patient outcomes in pre-clinical testing and the development has been expanded to encompass a wide array of biologic processes for production and formulation, as well as diagnostic and testing methodologies for novel T-cell applications.


Drugs Protected by US Patent 10,933,060

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Noden Pharma GOPRELTO cocaine hydrochloride SOLUTION;NASAL 209963-001 Dec 14, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES ⤷  Subscribe
Omnivium Pharms NUMBRINO cocaine hydrochloride SOLUTION;NASAL 209575-001 Jan 10, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES ⤷  Subscribe
Omnivium Pharms NUMBRINO cocaine hydrochloride SOLUTION;NASAL 209575-001 Jan 10, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.